Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Bioventix Plc LSE:BVXP London Ordinary Share GB00B4QVDF07 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -85.00 -2.12% 3,920.00 3,900.00 3,950.00 4,005.00 3,895.00 4,005.00 5,718 16:35:21
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 10.3 8.2 139.4 28.1 204

Bioventix Share Discussion Threads

Showing 1401 to 1424 of 1450 messages
Chat Pages: 58  57  56  55  54  53  52  51  50  49  48  47  Older
DateSubjectAuthorDiscuss
24/10/2022
09:41
Superbly run company. Well done all.
igbertsponk
24/10/2022
07:17
2H Revenue was £7m. Looking back there doesn't seem to be much seasonal weighting here. Excellent results.
trident5
23/10/2022
10:02
Yep - I'm optimistic.
Suet

suetballs
23/10/2022
09:42
"As announced in our interim results to 31 December 2021, we had a slow start
to the financial year. However, in the second half, we have seen an
improvement in performance and our trading result for FY2022 as a whole is
likely to be significantly ahead of market expectations."

Well, we'll see what significantly meant on Monday.

Being old fashioned - GLAH

podgyted
26/9/2022
09:57
Depends on what fx rates analysts have been using in their forecasts, and how much they have changed. Possibly not that much (i.e. they were already lower than spot rate). Plus other companies will also benefit from the weak pound, not just BVXP.
stepone68
26/9/2022
07:59
Thought weak sterling would give this a boost this am.
Suet

suetballs
15/9/2022
10:51
@stepone68 - thanks for that - great work!
doctor888
15/9/2022
09:51
Well, because I've got nothing better to do, I looked back at previous updates. The last one, as mentioned above, was 2017 !

In it, they said, "revenues for the financial year ended 30 June 2017 are expected to be marginally in excess of £7M (2015/16: £5.5M). Since the cost-base of the Company continues to follow a similar shallow trajectory as in previous years, both revenues and profits before tax are expected to be ahead of market expectations for the year ended 30 June 2017"

So, they actually gave a figure for turnover there! Looking at my notes, forecasts in 2017 were saying revenues of 6.3m. After the update, forecasts were showing 7.06m. The actual came in at 7.25m. So that looks like a bit over 10% to me, and they only said 'ahead' (i.e. no mention of 'materially' or 'significantly').

In August 2016 they also gave a revenue number - "in excess of 5.3m", and once again simply said profits would be "ahead". Forecasts had been saying £4.8m. So, again it looks like they were about 10% ahead, and, in the end, turnover was £5.5m.

In both those years, though, the high margins meant that EPS was 30-40% above forecasts.

This year, they did use the word 'significantly', so we should surely expect at least 10%, if not more! So, I'm going to take a punt on 11.4m turnover, eps 150p, dividend 150p - and I'm actually hoping for slightly more!!

Fingers crossed,
StepOne

stepone68
14/9/2022
21:28
I’ve always regarded the words “materially221; and “significantly” as meaning more than 10% and more than 20% fwiw
alter ego
14/9/2022
17:26
It is very likely to be a record revenue for a 6 month period, but as you say, it is anyone's guess. Has anyone trawled through prior RNS to see what 'significantly ahead' suggests?
doctor888
14/9/2022
17:22
I suspect over £11m.

(Why do companies keep on saying significantly/materially/exceeding - just tell us the revenue number - we're not financially illiterate as opposed, seemingly, to the entire of the City.)

Unhelpfully finnCap have not updated their forecasts this morning - they are still showing £10.4m - so significantly ahead would lead me to at least £11m.

podgyted
14/9/2022
12:23
Anyone care to guess what the sales might be? I've not recorded any forecasts for a couple of years, since Sharecast stopped publishing them. I found some today on marketscreener.com which say 10.4m for the year ended in June. 6 months to end December was 4.73m, which means market expecting 5.7 for H2. Can we add 0.5m for out-performance, and possibly another 0.5 for exchange rate headwind, to get us somewhere over 11m?

Maybe it doesn't matter that much and the main thing will be Troponin performance and pipeline progress.

stepone68
14/9/2022
08:56
Such a well run company. Bravo!
igbertsponk
14/9/2022
08:10
Imagine if the RNS came out on a positive day for the general market !!!

Roll on October 24.

jurgenklopp
14/9/2022
07:52
That's the first update they've put out in the last 5 years.
trident5
14/9/2022
06:30
Good trading update:

- fy2022 trading is likely to be signifcantly ahead of market expectations.
- hope that this recovery will be sustained and long lasting.
- 50% of revenues are in US$ with favourable exchange rates.

Nice to have some good news!!
Suet

suetballs
30/3/2022
15:15
Is that animal, vegetable or mineral?
Are yoy born with it, can you develop it or do you need to buy it?

redartbmud
30/3/2022
14:48
It's all down to the "Tau" of Peter Harrison
boros10
30/3/2022
13:38
Good reaction after disappointing results. The Company still trusted it seems.
igbertsponk
28/3/2022
09:03
Oops - well they are scientists!
Suet

suetballs
28/3/2022
08:21
Interims ...

"Board is pleased to announce a first interim dividend of 52p per share which represents a 20% increase on the interim dividend paid last year (43 pence per share). The shares will be marked ex-dividend on the 7 April 2021 and the dividend will be paid on 22 April 2021 to shareholders on the register at close of business on 8 April 2021."

!!

piedro
15/3/2022
08:52
Good news for our investment. Perhaps a catalyst for the share price Looking forward to results.

hxxps://www.bioworld.com/articles/516919-cardinor-secures-ce-mark-for-cardiovascular-risk-test?v=preview

doctor888
20/1/2022
12:10
John, you were predicting a tenner 2 years ago. You might be right eventually, but not yet :-)
stepone68
24/11/2021
17:32
https://www.dailymail.co.uk/news/article-10238113/New-Botswana-variant-32-horrific-mutations-evolved-Covid-strain-EVER.html
onjohn
Chat Pages: 58  57  56  55  54  53  52  51  50  49  48  47  Older
Your Recent History
LSE
BVXP
Bioventix
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20230126 22:00:33